Merck & Co Rating Reiterated by TheStreet (MRK)
Merck & Co (NYSE:MRK)‘s stock had its “buy” rating restated by TheStreet in a research note issued on Thursday, AnalystRatingsNetwork reports.
The analysts wrote, “Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of B+. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Shares of Merck & Co (NYSE:MRK) traded up 0.13% during mid-day trading on Thursday, hitting $47.733. The stock had a trading volume of 2,500,573 shares. Merck & Co has a one year low of $40.02 and a one year high of $50.16. The stock has a 50-day moving average of $47.82 and a 200-day moving average of $46.99. The company has a market cap of $139.7 billion and a price-to-earnings ratio of 28.54.
Merck & Co (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $0.84 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter last year, the company posted $1.05 earnings per share. Merck & Co’s revenue was down 10.6% compared to the same quarter last year. Analysts expect that Merck & Co will post $3.48 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on MRK. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co (NYSE:MRK) in a research note to investors on Thursday, September 12th. They now have a $51.00 price target on the stock. Separately, analysts at BMO Capital Markets raised their EPS on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday, September 10th. They now have a “market perform” rating and a $50.00 price target on the stock. Finally, analysts at Leerink Swann raised their EPS on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday, August 20th. They now have a “market perform” rating and a $48.40 price target on the stock. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. Merck & Co currently has an average rating of “Hold” and a consensus price target of $51.03.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.